Innovent Biologics, Inc. (IVBXF)
USD 6.88
(25.23%)
USD 6.88
(25.23%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 6.2 Billion | 4.55 Billion | 4.26 Billion | 3.84 Billion | 1.04 Billion | 9.47 Million |
| Cost of Revenue | 1.8 Billion | 930.99 Million | 573.04 Million | 387.76 Million | 124.87 Million | - |
| Gross Profit | 4.39 Billion | 3.62 Billion | 3.69 Billion | 3.45 Billion | 922.64 Million | 9.47 Million |
| Operating Expenses | 5.06 Billion | 6.2 Billion | 6.04 Billion | 3.49 Billion | 2.7 Billion | 1.56 Billion |
| Selling, General and Administrative Expenses | 3.85 Billion | 3.42 Billion | 3.61 Billion | 1.77 Billion | 1.44 Billion | 413.5 Million |
| Research and Development Expenses | 2.22 Billion | 2.87 Billion | 2.47 Billion | 1.85 Billion | 1.29 Billion | 1.22 Billion |
| Other Expenses | - | -433.63 Million | -717.41 Million | -384.05 Million | 144.08 Million | -4.33 Billion |
| Cost and Expenses | 7.88 Billion | 7.13 Billion | 6.61 Billion | 3.88 Billion | 2.82 Billion | 1.56 Billion |
| Operating Income | -1.67 Billion | -2.07 Billion | -3.11 Billion | -820.13 Million | -1.66 Billion | -5.8 Billion |
| Interest Expense | 98.62 Million | 101.69 Million | 62.46 Million | 68.35 Million | 59.49 Million | 68.96 Million |
| Income Tax Expense | -116.49 Million | 8.8 Million | 87.03 Million | 139.7 Million | 86.19 Million | -101.49 Million |
| Earnings before Tax | -1.14 Billion | -2.17 Billion | -3.05 Billion | -858.71 Million | -1.71 Billion | -5.87 Billion |
| Net Income | -1.02 Billion | -2.17 Billion | -3.13 Billion | -998.42 Million | -1.71 Billion | -5.77 Billion |
| Earnings Per Share Basic | -0.66 | -1.46 | -2.16 | -0.74 | -1.46 | -17.24 |
| Earnings Per Share Diluted | -0.66 | -1.46 | -2.16 | -0.74 | -1.46 | -17.24 |
| Weighted Average Shares Outstanding | 1.55 Billion | 1.49 Billion | 1.45 Billion | 1.35 Billion | 1.17 Billion | 334.68 Million |
| Weighted Average Shares Outstanding (Diluted) | 1.55 Billion | 1.49 Billion | 1.45 Billion | 1.35 Billion | 1.17 Billion | 334.68 Million |
| Gross Margin | 0.71 | 0.80 | 0.87 | 0.90 | 0.88 | 1.00 |
| EBIT Margin | -0.11 | -0.39 | -0.68 | -0.19 | -1.51 | -605.86 |
| Profit Margin | -0.17 | -0.48 | -0.73 | -0.26 | -1.64 | -609.00 |
| EBITDA | -660.68 Million | -1.74 Billion | -2.37 Billion | -704.73 Million | -1.57 Billion | -5.73 Billion |
| Earnings Before Tax Margin | -0.27 | -0.46 | -0.73 | -0.21 | -1.59 | -612.62 |
| Breakdown | 2024 Q2 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Revenue | 548.32 Million | 6.2 Billion | 484.73 Million | 240 Million | 389.76 Million | 196.68 Million |
| Cost of Revenue | 94 Million | 1.13 Billion | 87.36 Million | 70.2 Million | 72.8 Million | 56.91 Million |
| Gross Profit | 454.32 Million | 5.06 Billion | 397.36 Million | 169.8 Million | 316.96 Million | 139.77 Million |
| Operating Expenses | 499.25 Million | 5.97 Billion | 475.79 Million | 258.33 Million | 380.68 Million | 154.75 Million |
| Selling, General and Administrative Expenses | 305.1 Million | - | 295.32 Million | 146.22 Million | 247.54 Million | 124.92 Million |
| Research and Development Expenses | 194.15 Million | - | 180.46 Million | 89.35 Million | 133.13 Million | 67.18 Million |
| Other Expenses | - | -680.09 Million | - | - | - | - |
| Cost and Expenses | 593.25 Million | 7.11 Billion | 563.15 Million | 328.54 Million | 453.49 Million | 211.67 Million |
| Operating Income | -44.92 Million | -1.67 Billion | -78.42 Million | -57.87 Million | -63.72 Million | -52.33 Million |
| Interest Expense | 5.27 Million | 98.62 Million | 6.68 Million | - | 7.25 Million | - |
| Income Tax Expense | 4855.77 | -116.49 Million | 63.9 Thousand | 31.63 Thousand | -16.87 Million | 8.51 Million |
| Earnings before Tax | -54.46 Million | -1.14 Billion | -122.86 Million | -60.83 Million | -36.95 Million | -18.64 Million |
| Net Income | -54.47 Million | -1.02 Billion | -122.92 Million | -60.86 Million | -20.07 Million | -10.13 Million |
| Earnings Per Share Basic | -0.03 | - | -0.08 | -0.04 | -0.01 | -0.01 |
| Earnings Per Share Diluted | -0.03 | - | -0.08 | -0.04 | -0.01 | -0.01 |
| Weighted Average Shares Outstanding | 1.62 Billion | 1.55 Billion | 1.56 Billion | 1.57 Billion | 1.53 Billion | 1.53 Billion |
| Weighted Average Shares Outstanding (Diluted) | 1.62 Billion | 1.55 Billion | 1.56 Billion | 1.58 Billion | 1.53 Billion | 1.53 Billion |
| Gross Margin | 0.83 | 0.82 | 0.82 | 0.71 | 0.81 | 0.71 |
| EBIT Margin | -0.08 | - | -0.11 | -0.21 | -0.09 | -0.20 |
| Profit Margin | -0.10 | -0.17 | -0.25 | -0.25 | -0.05 | -0.05 |
| EBITDA | -44.92 Million | - | -51.11 Million | -50.79 Million | -36.65 Million | -39.79 Million |
| Earnings Before Tax Margin | -0.08 | -0.27 | -0.16 | -0.24 | -0.16 | -0.27 |
ZEO
DMAS
6618
3989
PREMIER
CPW